Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) — Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process